Increased expression of RhoC correlates with progression and poor prognosis of ductal adenocarcinoma of pancreas [123], hepatocellular cancer [124], breast cancer [109], ovarian cancer [110], bladder cancer [111], gastric cancer [125], esophageal SCC [113], head and neck SCC [120], prostate cancer [126], and non-small cell lung carcinoma (NSCLC) [127]. This evidence concerns the gene RHOC and breast carcinoma.